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Introduction {#brb3487-sec-0005}
============

Intracerebral hemorrhage (ICH) causes approximately 15% of all strokes in Western populations and 20--30% of all strokes in the Chinese population (Zhao et al. [2008](#brb3487-bib-0051){ref-type="ref"}; Wang et al. [2011](#brb3487-bib-0046){ref-type="ref"}). Patients with ICH generally have a poorer prognosis and higher mortality than do those with ischemic stroke (Biffi et al. [2011](#brb3487-bib-0005){ref-type="ref"}). Currently, no proven effective treatment for ICH exists. Therefore, preventing ICH to reduce the healthcare burden associated with hemorrhage stroke and other corresponding negative outcomes is critical.

HMG‐CoA reductase inhibitors, commonly known as statins, have been demonstrated to be beneficial in the primary and secondary prevention of ischemic stroke (Amarenco and Labreuche [2009](#brb3487-bib-0002){ref-type="ref"}; Stone et al. [2013](#brb3487-bib-0036){ref-type="ref"}). However, concerns have been raised about the risk of cerebral hemorrhage associated with statin use (Mascitelli and Pezzetta [2009](#brb3487-bib-0024){ref-type="ref"}; Vergouwen et al. [2009](#brb3487-bib-0044){ref-type="ref"}). This risk might be of major relevance to patients with prior ICH, who are at high risk of hemorrhage, which could result from the statin‐induced reductions in cholesterol levels and inhibition of platelet aggregation (Ricard et al. [2010](#brb3487-bib-0031){ref-type="ref"}). These concerns are particularly relevant to Asians, a population at higher risk of ICH (Tanaka et al. [1982](#brb3487-bib-0039){ref-type="ref"}; Hu et al. [1992](#brb3487-bib-0018){ref-type="ref"}).

Animal studies have shown that statins benefit neurological recovery, endothelial stabilization, and anti‐inflammatory activity because of their ability to reduce lipids (Giannopoulos et al. [2012](#brb3487-bib-0012){ref-type="ref"}; Yang et al. [2013a](#brb3487-bib-0049){ref-type="ref"},[b](#brb3487-bib-0050){ref-type="ref"}). However, statins may also have antithrombotic properties because they can inhibit platelet aggregation and enhance fibrinolysis, which might amplify the risk of ICH (Goldstein [2013](#brb3487-bib-0013){ref-type="ref"}). Most studies have supported the use of statins in patients before ICH (Leker et al. [2009](#brb3487-bib-0022){ref-type="ref"}; Eichel et al. [2010](#brb3487-bib-0009){ref-type="ref"}; Gomis et al. [2010](#brb3487-bib-0016){ref-type="ref"}; King et al. [2012](#brb3487-bib-0019){ref-type="ref"}; Mustanoja et al. [2013](#brb3487-bib-0027){ref-type="ref"}; Winkler et al. [2013](#brb3487-bib-0048){ref-type="ref"}) and after ICH (Flint et al. [2014](#brb3487-bib-0010){ref-type="ref"}; Pan et al. [2014](#brb3487-bib-0029){ref-type="ref"}; Chen et al. [2015](#brb3487-bib-0007){ref-type="ref"}), and they have concluded that statins promote favorable functional outcome and low mortality. However, most of those studies have focused on the association between the timing of statin use (Leker et al. [2009](#brb3487-bib-0022){ref-type="ref"}; Eichel et al. [2010](#brb3487-bib-0009){ref-type="ref"}; Gomis et al. [2010](#brb3487-bib-0016){ref-type="ref"}; King et al. [2012](#brb3487-bib-0019){ref-type="ref"}; Mustanoja et al. [2013](#brb3487-bib-0027){ref-type="ref"}; Winkler et al. [2013](#brb3487-bib-0048){ref-type="ref"}; Flint et al. [2014](#brb3487-bib-0010){ref-type="ref"}; Pan et al. [2014](#brb3487-bib-0029){ref-type="ref"}; Chen et al. [2015](#brb3487-bib-0007){ref-type="ref"}) or continuing (discontinuing) statin therapy (Dowlatshahi et al. [2012](#brb3487-bib-0008){ref-type="ref"}; Bustamante and Montaner [2013](#brb3487-bib-0006){ref-type="ref"}; Goldstein [2013](#brb3487-bib-0013){ref-type="ref"}; Scheitz et al. [2013](#brb3487-bib-0033){ref-type="ref"}; Tapia‐Perez et al. [2013](#brb3487-bib-0040){ref-type="ref"}) and the outcomes after a diagnosis of ICH. They have rarely considered the differences in the types of statin used or the differences in regimens and their association with outcomes in patients with newly diagnosed ICH. In addition, the mean follow‐up duration in statin and ICH trials is short, usually lasting 24 months or fewer. We performed a 10‐year population‐based cohort study to explore the relationship between the characteristics of post‐ICH statin use and the long‐term outcomes in patients with newly diagnosed ICH. The findings of such a study can provide useful information on the effective clinical use of these agents in patients after diagnosis of ICH for reducing the risk of recurrent ICH and hemorrhage stroke.

Methods {#brb3487-sec-0006}
=======

Ethics statement {#brb3487-sec-0007}
----------------

The database we used comprised de‐identified secondary data, and the study met the requirements of the Personal Information Protection Act of Taiwan. Because the analyzed data were anonymized, the need for informed consent was waived by the Institutional Review Board of Kaohsiung Medical University Hospital, Taiwan (KMUHIRB‐EXEMPT (I)‐20150027).

Data sources {#brb3487-sec-0008}
------------

We conducted this cohort study by using a sampling cohort data set obtained from the National Health Insurance Research Database (NHIRD) containing claims data for patients enrolled in Taiwan\'s National Health Insurance (NHI) program. The program has provided mandatory universal health insurance since 1995, covers up to 99% of all the residents of Taiwan, and contracts with 97% of all the medical providers in Taiwan. The NHIRD is a randomly selected data set of one million NHI claims from the year 2000 registry of all NHI enrollees (NHI 2000). We retrospectively and prospectively followed these patients from January 1, 1997 to December 31, 2010. According to the National Health Research Institutes, there are no significant differences in age, sex, and healthcare costs between the sampled group and all enrollees in NHI 2000 (National Health Insurance Research Database [2000](#brb3487-bib-0028){ref-type="ref"}). The database contains comprehensive demographic data, including sex, date of birth, and income level, as well as healthcare data, including the date of admission or discharge, clinical diagnoses (up to five coexisting diagnoses listed on one claims record), medical procedures (up to five diagnostic or therapeutics procedures), expenditures, detailed drug prescriptions, and in‐hospital deaths. The NHI lists diagnoses according to the codes of the *International Classification of Diseases, Ninth Revision, Clinical Modification* (ICD‐9‐CM) (2005).

Cohort population {#brb3487-sec-0009}
-----------------

We enrolled participants admitted for newly diagnosed ICH from January 1, 2001 to December 31, 2010 who had received initial brain computed tomography (CT) scans upon admission. We screened eligible participants on the basis of the principal diagnosis recorded in the NHIRD. We identified 4896 patients with a diagnosis of ICH (ICD‐9 CM: 431). Participants were excluded if they (1) had been admitted to hospitals because of a recurrent ICH within 1 year of their recruitment (*n *=* *97), (2) had not used statin after the ICH event for which they were recruited (*n *=* *3992), (3) had incomplete registration information (*n *=* *23), (4) had incomplete medical records within 1 year of their recruitment (*n *=* *37), or (5) had no available follow‐up data after discharge (*n *=* *21). We finally enrolled 726 patients for the statistical analysis.

Definition of the characteristics of statin initiation {#brb3487-sec-0010}
------------------------------------------------------

Patients with at least one statin prescription after enrollment were studied, and their first prescription of statin was defined as their initial usage. We categorized initial statin usage into high‐, moderate‐, and low‐intensity categories according to the average expected LDL--C response to a specific statin and dose outlined in the *2013 ACC/AHA Guideline* (Stone et al. [2013](#brb3487-bib-0036){ref-type="ref"}). Of the 726 patients, 92 were categorized as "high‐intensity" statin users, 545 as "moderate‐intensity" statin users, and 89 as "low‐intensity" statin users. Additional analyses were performed, and they entailed stratifying the statin therapies by hydrophilic and lipophilic solubility (water and oil solubility) (Serajuddin et al. [1991](#brb3487-bib-0035){ref-type="ref"}; Rosenson [2004](#brb3487-bib-0032){ref-type="ref"}). Moreover, of the enrolled patients, 431 were categorized as lipophilic statin users and 295 as hydrophilic statin users. Figure [1](#brb3487-fig-0001){ref-type="fig"} displays a flowchart of participant enrollment and category assignment.

![Participant enrollment flowchart.](BRB3-6-e00487-g001){#brb3487-fig-0001}

Study endpoints and follow‐up {#brb3487-sec-0011}
-----------------------------

The primary outcome of interest was recurrent ICH (ICD‐9‐CM code 431) diagnosed through CT scanning during admission. Secondary endpoints included individual components of ischemic stroke (ICD‐9‐CM codes 433, 434, 436, 437.1, and 437.9), transient ischemic attack (TIA; ICD‐9‐CM code 435), or acute coronary events (ICD‐9‐CM code 410). Moreover, all‐cause mortality was included as of one these secondary endpoints. However, because some Taiwanese patients prefer to pass away at home rather than in a hospital, the NHIRD contains no death records for patients who passed away at home. To determine deaths, we first assumed that patients with ICH required long‐term follow‐up and medication use; we subsequently assumed that a patient had passed away when he or she had no claims data associated with a physician visit or prescription in the NHIRD for more than 30 days following ICH diagnosis or when he or she had a death record in the NHIRD. The occurrence of other negative study outcomes (recurrent ICH, acute coronary events, or ischemic stroke or attack) was identified on the basis of diagnoses recorded in the ambulatory and hospitalization claims of the NHIRD. Eligible patients were followed up from the date of their first statin prescription to the date of their final medical record or before the end of the study period (December 31, 2010). We censored patients who did not reach the outcomes of interest.

Statistical analysis {#brb3487-sec-0012}
--------------------

The basic characteristics, comorbid diseases, and medical histories of each participant were recorded and analyzed from the data registered in the NHIRD. Charlson comorbidity index adjustments to the ICH outcomes were used to adjust the comorbidity of each participant (Goldstein et al. [2004](#brb3487-bib-0014){ref-type="ref"}). Continuous variables are described as means ± standard deviation, and categorical variables are described in patient numbers and percentages. ANOVA or a Student\'s *t* test was used for normally distributed continuous variables between groups, whereas chi‐squared tests were used to compare categorical variables. Variables with a two‐tailed *P* value \<0.05 were considered significant. The event‐free time to the composite endpoints is presented as a Kaplan--Meier survival curve stratified by the characteristics of statin initiation. The time‐dependent Cox proportional hazards model was used to examine the relationship between the endpoints and characteristics of initial statin therapy. Hazard ratios (HRs) and their corresponding 95% confidence intervals (CIs) were calculated. All statistical operations were performed using SAS for Windows Version 9.2 (SAS Institute, Inc., Cary, NC).

Results {#brb3487-sec-0013}
=======

Baseline characteristics of different groups {#brb3487-sec-0014}
--------------------------------------------

Tables [1](#brb3487-tbl-0001){ref-type="table-wrap"} and [2](#brb3487-tbl-0002){ref-type="table-wrap"} show the baseline characteristics of the different groups of patients with newly diagnosed ICH. The three groups involving different usage intensity levels were similar regarding the proportion of males and females, comorbidities, and comedications, but not antiarrhythmic agents (Table [1](#brb3487-tbl-0001){ref-type="table-wrap"}). The two statin solubility groups also exhibited similar proportions of males and females, comorbidities, and comedications, but not the comorbidity of ischemic stroke (Table [2](#brb3487-tbl-0002){ref-type="table-wrap"}). Moreover, 75.1% of the patients were moderate‐intensity statin users, and 59.4% were prescribed lipophilic statins.

###### 

Baseline characteristics according to intensity of statin initiation; data presented as *n*, (%), *n* = 726

  Characteristics                                                   High (*n* = 92)   Moderate (*n *=* *545)   Low (*n *=* *89)   *P* [a](#brb3487-note-0004){ref-type="fn"} value
  ----------------------------------------------------------------- ----------------- ------------------------ ------------------ --------------------------------------------------
  Age (Mean ± SD)                                                   58.91 ± 12.70     60.72 ± 12.28            60.92 ± 12.48      0.4074
  Male                                                              52 (56.52)        300 (55.05)              53 (59.55)         0.7216
  Charlson index                                                                                                                  
  0                                                                 40 (43.48)        234 (42.94)              31 (34.83)         0.5506
  1                                                                 19 (20.65)        133 (24.40)              26 (29.21)         
  ≧2                                                                33 (35.87)        178 (32.66)              32 (35.96)         
  Comorbidities                                                                                                                   
  Hypertension                                                      53 (57.61)        312 (57.25)              56 (62.92)         0.6013
  Diabetes mellitus                                                 25 (27.17)        152 (27.89)              27 (30.34)         0.8731
  Hyperlipidemia                                                    22 (23.91)        127 (23.30)              29 (32.58)         0.1668
  Atrial fibrillation                                               3 (3.26)          19 (3.49)                2 (2.25)           0.8319
  Coronary artery disease                                           15 (16.30)        89 (16.33)               15 (16.85)         0.9921
  Ischemic stroke                                                   18 (19.57)        95 (17.43)               13 (14.61)         0.6756
  Co‐medication in previous 1 year                                                                                                
  Antiarrhythmic agents                                             7 (7.61)          75 (13.76)               18 (20.22)         0.0483[a](#brb3487-note-0004){ref-type="fn"}
  Anticoagulant agents                                              7 (7.61)          55 (10.09)               9 (10.11)          0.7547
  Antiplatelet agents                                               51 (55.43)        333 (61.10)              62 (69.66)         0.1376
  Antidiabetic agents                                               40 (43.48)        265 (48.62)              40 (44.94)         0.5753
  ACEi/ARB                                                          81 (88.04)        507 (93.03)              80 (89.89)         0.1938
  Beta blockers                                                     80 (86.96)        494 (90.64)              82 (92.13)         0.4505
  Calcium channel blockers                                          85 (92.39)        496 (91.01)              82 (92.13)         0.8719
  Diuretics                                                         72 (78.26)        428 (78.53)              71 (79.78)         0.9608
  Digoxin                                                           9 (9.78)          459 (15.78)              73 (17.98)         0.2526
  Other dyslipidemic agents[b](#brb3487-note-0005){ref-type="fn"}   42 (43.48)        223 (40.92)              40 (44.94)         0.7256

ACEi, angiotensin‐converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

High intensity: atorvastatin 40--80 mg, rosuvastatin 20--40 mg; Moderate intensity: atorvastatin 10--20 mg, rosuvastatin 5--10 mg, simvastatin 20--40 mg, pravastatin 40--80 mg, lovastatin 40 mg, fluvastatin XL 80 mg, fluvastatin 40 mg bid, pitavastatin 2--4 mg; Low intensity: simvastatin 10 mg, pravastatin 10--20 mg, lovastatin 20 mg, fluvastatin 20--40 mg, pitavastatin 1 mg.

ANOVA for continuous variables; Chi‐squared test for categorical variables.

Other dyslipidemic agents include cholestyramine, fibrates, and niacin.
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###### 

Baseline characteristics according to solubility of statin; data presented as *n*, (%), *n *=* *726

  Characteristics                                                   Lipophilic (*n *=* *431)   Hydrophilic (*n* = 295)   *P* [a](#brb3487-note-0008){ref-type="fn"} value
  ----------------------------------------------------------------- -------------------------- ------------------------- --------------------------------------------------
  Age (Mean ± SD)                                                   60.48 ± 12.58              60.57 ± 12.05             0.9279
  Male                                                              240 (55.68)                165 (55.93)               0.9474
  Charlson index                                                                                                         
  0                                                                 176 (40.84)                129 (43.73)               0.4637
  1                                                                 103 (23.90)                75 (25.42)                
  ≧2                                                                152 (35.27)                91 (30.85)                
  Comorbidities                                                                                                          
  Hypertension                                                      247 (57.31)                174 (58.98)               0.6535
  Diabetes mellitus                                                 122 (28.31)                82 (27.80)                0.8807
  Hyperlipidemia                                                    109 (25.29)                69 (23.39)                0.5589
  Atrial fibrillation                                               15 (3.48)                  9 (3.05)                  0.7506
  Coronary artery disease                                           66 (15.31)                 53 (17.97)                0.3430
  Ischemic stroke                                                   86 (19.95)                 40 (13.56)                0.0255[a](#brb3487-note-0008){ref-type="fn"}
  Co‐medication in previous 1 year                                                                                       
  Antiarrhythmic agents                                             62 (14.39)                 38 (12.88)                0.5636
  Anticoagulant agents                                              42 (9.74)                  29 (9.83)                 0.9695
  Antiplatelet agents                                               277 (64.27)                169 (57.29)               0.0577
  Antidiabetic agents                                               197 (45.71)                148 (50.17)               0.2371
  ACEi/ARB                                                          393 (91.18)                275 (93.22)               0.3201
  Beta blockers                                                     385 (89.33)                271 (91.86)               0.2553
  Calcium channel blockers                                          390 (90.49)                273 (92.54)               0.3340
  Diuretics                                                         336 (77.96)                235 (79.66)               0.5824
  Digoxin                                                           64 (14.85)                 47 (15.93)                0.6904
  Other dyslipidemic agents[b](#brb3487-note-0009){ref-type="fn"}   172 (39.91)                131 (44.41)               0.2272

ACEi: angiotensin‐converting enzyme inhibitor; ARB: angiotensin II receptor blocker.

Hydrophilic solubility: pravastatin, rosuvastatin; Lipophilic solubility: atorvastatin, cerivastatin, fluvastatin, lovastatin, simvastatin.

Student *t* test for continuous variables; Chi‐squared test for categorical variables.

Other dyslipidemic agents include cholestyramine, fibrates, and niacin.
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Cumulative incidence and hazard ratio of the composite endpoints among the high‐, moderate‐, and low‐intensity groups during follow‐up {#brb3487-sec-0015}
--------------------------------------------------------------------------------------------------------------------------------------

The endpoints were assessed in the three groups with varying statin intensities (high, moderate, and low; Table [3](#brb3487-tbl-0003){ref-type="table-wrap"}). During the follow‐up period, 135 (18.6%) patients developed one of the adverse outcomes of interest. Of these patients, 15 (16.3%) were high‐intensity statin users, 109 (20.0%) were moderate‐intensity users, and 11 (12.4%) were low‐intensity users (Table [3](#brb3487-tbl-0003){ref-type="table-wrap"}). Compared with the patients in the high‐intensity group, those in the low‐intensity group demonstrated no significant difference in the incidence of recurrent ICH (adjusted HR \[aHR\] = 0.66, 95% CI = 0.30--1.44), all‐cause mortality (aHR = 0.65, 95% CI = 0.28--1.55), ischemic stroke or TIA (aHR = 0.96, 95% CI = 0.67--1.38), or acute coronary events (aHR = 1.69, 95% CI = 0.17--16.68). Moreover, the patients in the moderate‐intensity group had no significant difference in the incidence of all‐cause mortality (aHR = 0.75, 95% CI = 0.38--1.48), recurrent ICH (aHR = 1.19, 95% CI = 0.69--2.05), acute coronary events (aHR = 2.15, 95% CI = 0.28--16.30), or ischemic stroke or TIA (aHR = 1.07, 95% CI = 0.81--1.42; Table [3](#brb3487-tbl-0003){ref-type="table-wrap"}).

###### 

Multivariable‐adjusted relationships between the intensity (high, moderate, and low) of statin use and outcomes

  Characteristics                                      High (*n* = 92)   Moderate (*n* = 545)   Low (*n* = 89)
  ---------------------------------------------------- ----------------- ---------------------- --------------------
  Recurrent ICH, *n* (%)                               15 (16.3)         109 (20.0)             11 (12.4)
  Multivariable Adjusted OR (95% CI)                   1.00 (--)         1.19 (0.69--2.05)      0.66 (0.30--1.44)
  Death (all cause), *n* (%)                           10 (10.9)         70 (12.8)              13 (14.6)
  Multivariable Adjusted OR (95% CI)                   1.00 (--)         0.75 (0.38--1.48)      0.65 (0.28--1.55)
  Acute coronary event, *n* (%)                        1 (1.1)           19 (3.5)               3 (3.4)
  Multivariable Adjusted OR (95% CI)                   1.00 (--)         2.15 (0.28--16.30)     1.69 (0.17--16.68)
  Ischemic stroke/Transient ischemic attack, *n* (%)   58 (63.0)         380 (69.7)             66 (74.2)
  Multivariable Adjusted OR (95% CI)                   1.00 (--)         1.07 (0.81--1.42)      0.96 (0.67--1.38)

CI, confidence interval; ICH, intracerebral hemorrhage.

High intensity: atorvastatin 40--80 mg, rosuvastatin 20--40 mg; Moderate intensity: atorvastatin 10--20 mg, rosuvastatin 5--10 mg, simvastatin 20--40 mg, pravastatin 40--80 mg, lovastatin 40 mg, fluvastatin XL 80 mg, fluvastatin 40 mg bid, pitavastatin 2--4 mg; Low intensity: simvastatin 10 mg, pravastatin 10--20 mg, lovastatin 20 mg, fluvastatin 20--40 mg, pitavastatin 1 mg.

Adjusted variables include the following: age, sex, hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, coronary artery disease, ischemic stroke, anticoagulant agents, antiplatelet agents, calcium channel blockers, diuretics, digoxin, antidiabetic agents, other dyslipidemic agents, and preuse of statin.
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Cumulative incidence and hazard ratio of the composite endpoints between hydrophilic and lipophilic groups during follow‐up {#brb3487-sec-0016}
---------------------------------------------------------------------------------------------------------------------------

The endpoints were assessed in the two statin solubility groups (hydrophilic and lipophilic; Table [4](#brb3487-tbl-0004){ref-type="table-wrap"}). During the follow‐up period, 135 (18.6%) patients had one of the adverse study outcomes, and of these patients, 43 (14.6%) were users of hydrophilic statins and 92 (21.4%) were users of lipophilic statins. Compared with the patients using lipophilic statins, those using hydrophilic statins had a significantly lower incidence of recurrent ICH (aHR: 0.69, 95% CI: 0.48--0.99), but no significantly different incidence of all‐cause mortality (aHR = 1.15, 95% CI = 0.74--1.78), acute coronary events (aHR = 1.33, 95% CI = 0.57--3.15), or ischemic stroke or TIA (aHR = 1.09, 95% CI = 0.91--1.31; Table [4](#brb3487-tbl-0004){ref-type="table-wrap"}).

###### 

Multivariable‐adjusted relationships between the solubility (hydrophilic and lipophilic) of statins and outcomes

  Characteristics                                      Lipophilic (*n* = 431)   Hydrophilic (*n* = 295)
  ---------------------------------------------------- ------------------------ ---------------------------------------------------------
  Recurrent ICH, *n* (%)                               92 (21.4)                43 (14.6)
  Multivariable Adjusted OR (95% CI)                   1.00 (--)                0.69 (0.48--0.99)[a](#brb3487-note-0016){ref-type="fn"}
  Death (all cause), *n* (%)                           56 (13.0)                37 (12.5)
  Multivariable Adjusted OR (95% CI)                   1.00 (--)                1.15 (0.74--1.78)
  Acute coronary event, *n* (%)                        12 (2.8)                 11 (3.7)
  Multivariable adjusted OR (95% CI)                   1.00 (--)                1.33 (0.57--3.15)
  Ischemic stroke/Transient ischemic attack, *N* (%)   298 (69.1)               206 (69.8)
  Multivariable adjusted OR (95% CI)                   1.00 (--)                1.09 (0.91--1.31)

Hydrophilic solubility: pravastatin, rosuvastatin; Lipophilic solubility: atorvastatin, cerivastatin, fluvastatin, lovastatin, simvastatin.

Adjusted variables include the following: age, sex, hypertension, diabetes mellitus, hyperlipidemia, atrial fibrillation, coronary artery disease, ischemic stroke, anticoagulant agents, antiplatelet agents, calcium channel blockers, diuretics, digoxin, antidiabetic agents, other dyslipidemic agents, and preuse of statin.

ICH, intracerebral hemorrhage; CI, confidence interval.

*P *\<* *0.05.
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Figure [2](#brb3487-fig-0002){ref-type="fig"} illustrates a Kaplan--Meier curve representing the probability of an event occurring during the follow‐up period in the three statin‐intensity groups and two solubility groups. Although we observed no significant differences in the recurrence of ICH (*P* = 0.1440) among the three statin intensity groups, we determined a significant difference (*P* = 0.0306) in the recurrence of ICH between the statin solubility groups.

![Kaplan--Meier survival curve for the probability of being event‐free at 6 years stratified by the intensity of statin therapy (A) and solubility of statin therapy (B).](BRB3-6-e00487-g002){#brb3487-fig-0002}

Discussion {#brb3487-sec-0017}
==========

By using Taiwan\'s nationwide NHI database, we determined that newly diagnosed ICH patients treated with hydrophilic statins had a lower risk of recurrent ICH during the follow‐up period than did those treated with lipophilic statins. We observed no significant relationship between the intensity of statin use and recurrent ICH or secondary outcomes.

The benefits of HMG‐CoA reductase inhibitors (statins) for the primary and secondary prevention of cardiac and cerebrovascular disease are adequately established (Amarenco et al. [2006](#brb3487-bib-0003){ref-type="ref"}; Gaspardone and Arca [2007](#brb3487-bib-0011){ref-type="ref"}; Ward et al. [2007](#brb3487-bib-0047){ref-type="ref"}). However, a previous trial, Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL), identified a minor increase in the risk of ICH (HR: 1.66; 95% CI: 1.08--2.55) associated with high‐dose statin use (Goldstein et al. [2008](#brb3487-bib-0015){ref-type="ref"}). Although another meta‐analysis found no association between statin use or low‐density cholesterol levels and ICH, statin therapy among patients at high risk for hemorrhage because of prior ICH still remains a concern. Furthermore, ICH survivors commonly have comorbid cardiovascular risk factors that would otherwise warrant cholesterol‐lowering medication; achieving a balance between the risk of ICH and ischemic vascular diseases for statin therapy in this population is considerably challenging.

In addition to cholesterol reduction (Takemoto and Liao [2001](#brb3487-bib-0038){ref-type="ref"}; Reiss and Wirkowski [2007](#brb3487-bib-0030){ref-type="ref"}), statins have pleiotropic effects, and some of them have been suggested to be possible mechanisms underlying increased ICH risks (Meier et al. [2009](#brb3487-bib-0026){ref-type="ref"}). For example, evidence shows that statins have antithrombotic (Szapary et al. [2004](#brb3487-bib-0037){ref-type="ref"}) and fibrinolytic (Aarons et al. [2007](#brb3487-bib-0001){ref-type="ref"}) effects in addition to enhancing the activity of other fibrinolytic agents (Undas et al. [2006](#brb3487-bib-0042){ref-type="ref"}). In a previous study, an association between increasing doses of statin and the risk of ICH was observed among European patients with acute ischemic stroke after intravenous thrombolysis (Scheitz et al. [2014](#brb3487-bib-0034){ref-type="ref"}). Another animal study revealed that high‐dose statin use exerted adverse effects on function and tissue recovery and that statin‐induced adverse effects may be dose‐related (Yang et al. [2013a](#brb3487-bib-0049){ref-type="ref"},[b](#brb3487-bib-0050){ref-type="ref"}). The mechanisms underlying the absence of a therapeutic effect of high‐dose statin use in this ICH model remain unknown. Historically, an elevated dosage of statins was believed to reduce the level of cholesterol linked with an increased rate of hemorrhagic stroke (Tirschwell et al. [2004](#brb3487-bib-0041){ref-type="ref"}; Goldstein et al. [2008](#brb3487-bib-0015){ref-type="ref"}). In addition, reports have suggested that the more lipid‐soluble a statin is, the greater is its propensity to cross the blood--brain barrier and affect the central nervous system and vessels in the brain (Goldstein et al. [2004](#brb3487-bib-0014){ref-type="ref"}). Therefore, potency and lipophilic solubility are expected to correlate with both the protective and adverse effects of statin usage. In addition, previous studies have compared statin users with nonstatin users (Hackam et al. [2012](#brb3487-bib-0017){ref-type="ref"}; Mckinney and Kostis [2012](#brb3487-bib-0025){ref-type="ref"}; Laloux [2013](#brb3487-bib-0020){ref-type="ref"}; Liu et al. [2013](#brb3487-bib-0023){ref-type="ref"}; Lei et al. [2014](#brb3487-bib-0021){ref-type="ref"}; Asberg and Eriksson [2015](#brb3487-bib-0004){ref-type="ref"}), and a recent nationwide observational study demonstrated that statin therapy was associated with a lower risk of ICH compared with nonstatin therapy (Asberg and Eriksson [2015](#brb3487-bib-0004){ref-type="ref"}). Most physicians in Taiwan comply with insurance regulations and prescribe statins to patients exhibiting related risk factors and high lipid profiles, satisfying the criteria of the NHI guidelines. Regarding comparability, we examined the relationship between the characteristics of statin use and the outcomes in post‐ICH patients, and we determined that the risks of developing recurrent ICH between the low‐ or moderate‐intensity users and the high‐intensity users were not significantly different. However, we identified hydrophilic statin users to be at significantly lower risk of developing recurrent ICH compared with lipophilic statin users. Therefore, compared with the intensity, which included dosage and potency, solubility may have been more critical to the safety of statin use. The findings of our study may serve as a reference for selecting statin regimens. Prospective randomized clinical studies are required to confirm these findings.

This study had several limitations. First, the diagnoses of hemorrhagic stroke in the NHIRD were not validated, and a misclassification of events might have occurred. To limit this possibility, we recruited only participants who were admitted to hospitals with a first diagnosis of ICH and subjected to a CT scan during the admission. These criteria were also applied to the outcome of recurrent ICH. Second, we could not control for out‐of‐pocket purchases and adherence to prescribed statin medication regimens, which could have resulted in a misclassification of exposure. However, this misclassification would have been unlikely because all statin products are reimbursable by the NHI program in Taiwan and because the problem of adherence to medication regimens has similar effects on each group. Third, serum cholesterol levels could not be identified in the claims records and were thus unavailable in our study. Hence, we could not evaluate the association between serum cholesterol levels and the risk of ICH. Nevertheless, data from the SPARCL trial (Goldstein et al. [2008](#brb3487-bib-0015){ref-type="ref"}) revealed no relationship between on‐treatment, low‐density lipoprotein cholesterol levels and the risk of hemorrhagic stroke in statin‐treated patients. Fourth, ICH is a heterogeneous entity with different locations, origins, and recurrence risks. In ICH survivors, the rate of ICH recurrence is different; this recurrence depends on various factors such as the type of bleeding, ex.: arterio‐venous malformation (AVM), cerebral aneurysm, and cerebral amyloid angiopathy (Viswanathan et al. [2006](#brb3487-bib-0045){ref-type="ref"}). In this study, we identified only two patients with AVM and three with cerebral amyloid angiopathy. The result was similar after these patients were excluded. However, we did not include detailed information for determining which location of cerebral bleeding might be influenced by statin, and our results might be carefully applied to a specific subtype of ICH patients (e.g., patients with lobar ICH). Fifth, although statistical adjustment was performed using multivariable models, residual, unmeasured confounders (e.g., cigarette smoking and excessive alcohol consumption) remain a concern. Finally, because our study was based on a homogeneous Asian population, the generalizability of our findings to other racial groups may be limited.

Conclusion {#brb3487-sec-0018}
==========

This 10‐year nationwide follow‐up cohort study of newly diagnosed ICH patients receiving statin therapy demonstrated that users of hydrophilic statins had a significantly lower risk of recurrent ICH than did users of lipophilic statins. Additionally, the intensity of statin use had no significant relationship with recurrent ICH or other secondary adverse outcomes. Additional prospective randomized clinical trials are required to confirm the favorable effects of hydrophilic statin therapy in ICH patients.
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